![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JQ Chen, A Strom, JA Gustafsson and ET Morgan
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Hepatic expression of various members of the cytochrome P-450 (CYP) superfamily is suppressed during inflammatory responses. We have shown that the specific expression of P-450 2C11 in male rat liver is suppressed transcriptionally by endotoxin treatment. To investigate the molecular mechanisms underlying this phenomenon, we studied the effects of the inflammatory cytokines interleukin (IL)-1, IL-6, tumor necrosis factor-alpha (TNF), interferon (IFN)-alpha, and IFN-gamma on the expression of P-450 2C11 and the mRNAs of two typical acute-phase protein genes, alpha 1-acid glycoprotein (AGP) and fibrinogen, in primary hepatocyte cultures. IL-1, IL-6, TNF, and IFN-alpha all suppressed P-450 2C11 mRNA, whereas IFN-gamma had no effect. IL-1 and TNF were more effective than IL-6 in the suppression of P-450 2C11 mRNA. Whereas IL-1 and IL-6 effects on P-450 2C11 were accompanied by induction of AGP and fibrinogen mRNAs, IFN-alpha and TNF treatments had no effects on AGP. The suppression of P-450 2C11 and the induction of AGP by IL-1 showed similar time courses. The combination of IL-1 and IL- 6 showed additivity in suppression of P-450 2C11, at maximally effective concentrations of cytokines. The effects of IL-1 on P-450 2C11 and AGP expression were blocked by IL-1 receptor antagonist protein. We also studied the effects of IL-1 and IL-6 on the transient expression of chloramphenicol acetyl-transferase reporter gene constructs containing 200 or 1287 base pairs of the 5' flanking region of the CYP2C11 gene, transfected into primary hepatocytes. The chloramphenicol acetyltransferase activities in cells transfected with the 200-base pair construct were reduced to about 33% and 58% of control levels by treatment with IL-1 or IL-6, respectively, suggesting that sequences important for cytokine down-regulation lie within the proximal promoter region of the CYP2C11 gene.
This article has been cited by other articles:
|
|
 |
|
  E. T. Morgan, K. B. Goralski, M. Piquette-Miller, K. W. Renton, G. R. Robertson, M. R. Chaluvadi, K. A. Charles, S. J. Clarke, M. Kacevska, C. Liddle, et al. Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer Drug Metab. Dispos., February 1, 2008; 36(2): 205 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-M. Lee, B.-Y. Kim, L. Li, and E. T. Morgan Nitric Oxide-dependent Proteasomal Degradation of Cytochrome P450 2B Proteins J. Biol. Chem., January 11, 2008; 283(2): 889 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Riddick, C. Lee, A. Bhathena, Y. E. Timsit, P.-Y. Cheng, E. T. Morgan, R. A. Prough, S. L. Ripp, K. K. M. Miller, A. Jahan, et al. TRANSCRIPTIONAL SUPPRESSION OF CYTOCHROME P450 GENES BY ENDOGENOUS AND EXOGENOUS CHEMICALS Drug Metab. Dispos., April 1, 2004; 32(4): 367 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Iber, T. Li-Masters, Q. Chen, S. Yu, and E. T. Morgan Regulation of Hepatic Cytochrome P450 2C11 via cAMP: Implications for Down-Regulation in Diabetes, Fasting, and Inflammation J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 174 - 180. [Abstract] [Full Text]
|
|
|
|
|
|
J. Pan, Q. Xiang, and S. Ball Use of a Novel Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction Method to Study the Effects of Cytokines on Cytochrome P450 mRNA Expression in Mouse Liver Drug Metab. Dispos., June 1, 2000; 28(6): 709 - 713. [Abstract] [Full Text]
|
|
|
|
 |
|
 M Murray Glucocorticoid-dependent maintenance of CYP2C11-dependent oxidation in male rat liver in vivo Human and Experimental Toxicology, February 1, 2000; 19(2): 126 - 131. [Abstract] [PDF]
|
|
|
|
|
|
K. Rockich and R. Blouin Effect of the Acute-Phase Response on the Pharmacokinetics of Chlorzoxazone and Cytochrome P-450 2E1 In Vitro Activity in Rats Drug Metab. Dispos., September 1, 1999; 27(9): 1074 - 1077. [Abstract] [Full Text]
|
|
|
|
|
|
M. Tinel, J. Elkahwaji, M. A. Robin, N. Fardel, V. Descatoire, D. Haouzi, A. Berson, and D. Pessayre Interleukin-2 Overexpresses c-myc and Down-Regulates Cytochrome P-450 in Rat Hepatocytes J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 649 - 655. [Abstract] [Full Text]
|
|
|
|
|
|
C. Vafeas, P. A. Mieyal, F. Urbano, J. R. Falck, K. Chauhan, M. Berman, and M. L. Schwartzman Hypoxia Stimulates the Synthesis of Cytochrome P450-Derived Inflammatory Eicosanoids in Rabbit Corneal Epithelium J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 903 - 910. [Abstract] [Full Text]
|
|
|
|
|
|
H. Iber and E. T. Morgan Regulation of Hepatic Cytochrome P450 2C11 by Transforming Growth Factor-beta , Hepatocyte Growth Factor, and Interleukin-11 Drug Metab. Dispos., October 1, 1998; 26(10): 1042 - 1044. [Abstract] [Full Text]
|
|
|
|
|
|
M. B. Sewer and E. T. Morgan Down-Regulation of the Expression of Three Major Rat Liver Cytochrome P450S by Endotoxin In Vivo Occurs Independently of Nitric Oxide Production J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 352 - 358. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. B. Sewer, T. B. Barclay, and E. T. Morgan Down-Regulation of Cytochrome P450 mRNAs and Proteins in Mice Lacking a Functional NOS2 Gene Mol. Pharmacol., August 1, 1998; 54(2): 273 - 279. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Levesque, M. Beaulieu, C. Guillemette, D. W. Hum, and A. Belanger Effect of Interleukins on UGT2B15 and UGT2B17 Steroid Uridine Diphosphate-Glucuronosyltransferase Expression and Activity in the LNCaP Cell Line Endocrinology, May 1, 1998; 139(5): 2375 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Guillén, M. T. Donato, R. Jover, J. V. Castell, R. Fabra, R. Trullenque, and M. J. Gómez-Lechón Oncostatin M Down-regulates Basal and Induced Cytochromes P450 in Human Hepatocytes J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 127 - 134. [Abstract] [Full Text]
|
|
|
|
|
|
S. G. Kim and S. H. Choi Gadolinium Chloride Inhibition of Rat Hepatic Microsomal Epoxide Hydrolase and Glutathione S-Transferase Gene Expression Drug Metab. Dispos., December 1, 1997; 25(12): 1416 - 1423. [Abstract] [Full Text]
|
|
|
|
|
|
M. Nikolova-Karakashian, E. T. Morgan, C. Alexander, D. C. Liotta, and A. H. Merrill Jr. Bimodal Regulation of Ceramidase by Interleukin-1beta . IMPLICATIONS FOR THE REGULATION OF CYTOCHROME P450 2C11 (CYP2C11) J. Biol. Chem., July 25, 1997; 272(30): 18718 - 18724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Donato, M. I. Guillén, R. Jover, J. V. Castell, and M. J. Gómez-Lechón Nitric Oxide-Mediated Inhibition of Cytochrome P450 by Interferon-gamma in Human Hepatocytes J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 484 - 490. [Abstract] [Full Text]
|
|
|
|
|
|
J.-P. Thissen and J. Verniers Inhibition by Interleukin-1{beta} and Tumor Necrosis Factor-{alpha} of the Insulin-Like Growth Factor I Messenger Ribonucleic Acid Response to Growth Hormone in Rat Hepatocyte Primary Culture Endocrinology, March 1, 1997; 138(3): 1078 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Sewer, D. R. Koop, and E. T. Morgan Differential Inductive and Suppressive Effects of Endotoxin and Particulate Irritants on Hepatic and Renal Cytochrome P-450 Expression J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1445 - 1454. [Abstract] [Full Text]
|
|
|
|
|
|
J. Chen, M. Nikolova-Karakashian, A. H. Merrill , Jr., and E. T. Morgan Regulation of Cytochrome P450 2C11 (CYP2C11) Gene Expression by Interleukin-1, Sphingomyelin Hydrolysis, and Ceramides in Rat Hepatocytes J. Biol. Chem., October 20, 1995; 270(42): 25233 - 25238. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
